Skip to main content

Market Overview

Hologic: Meet Goldman Sach's New 'Conviction Buy'

Hologic: Meet Goldman Sach's New 'Conviction Buy'

Hologic, Inc. (NASDAQ: HOLX) — the manufacturer of diagnostic products, medical imaging systems and surgical products — is being added to Goldman Sachs' conviction list.

The list is made up of Goldman's Buy-rated stocks that analysts said have the best alpha-generation opportunities. Alpha is the incremental return an asset generates over a related benchmark.

The Analyst

Goldman analyst Isaac Ro has a Buy rating on Hologic and raised the price target from $45 to $50.

The Thesis

The favorable setup into fiscal 2018 positions Hologic to outperform, especially after a lackluster 2017, analyst Ro said in a Thursday note. (See Ro's track record here.) 

Concerns surrounding Hologic's Cynosure acquisition are now behind the company, as the CEO decided to stay with the company after a contract renegotiation, Ro said. 

Investors may be underappreciating easy comps in the core business, particularly in the second half; double-digit growth in the ex-U.S. business and the potential upside from a tax reform, according to Goldman. 

The analyst projects 20 percent upside to his Hologic price target. 

Following its attendance of Hologic's key medical conferences a check thatevealed positive new product momentum, Goldman said the new product cycle in the diagnostic division will materially expand the addressable market.

The share loss to General Electric Company (NYSE: GE) in the Breast Health division may not be as bad as investors feared, Ro said. Goldman expects ramp of new product cycles in 2018 to help the company retain share.

Goldman views the following as potential catalysts for Hologic:

The fiscal first quarter report in February. 

  • The ASLMS conference in April. 
  • Easing comps in the second half. 
  • Tax reform.
  • Take-out potential.

The Price Action

Hologic shares are up over 10 percent year-to-date.

At the time of writing, the shares were rallying 1.42 percent to $42.27.

Related Links:

Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector

Intuitive Surgical Makes New All-Time High After Q3 Beat

Photo courtesy of Hologic. 

Latest Ratings for HOLX

Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings


Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs Isaac RoAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at